Security key
74346N701
Propanc Biopharma, Inc. - Common Stock, par value $0.001 per share (PPCB)
CUSIP: 74346N701
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 12,703,253
- Total 13F shares
- 128,890
- Share change
- +16,784
- Total reported value
- $69,467
- Reported price per share
- $0.54
- Number of holders
- 4
- Value change
- -$39,571
- Number of buys
- 3
- Number of sells
- 2
Security identity
Holder snapshot
Report period
Q4 2025
Institutions
4
Top holders
4
PPCB full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Propanc Biopharma, Inc. SEC filings
Propanc Biopharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74346N701
Recent filing periods:
Ownership snapshot
Top reported holders of PPCB - Propanc Biopharma, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
Marex Group plc
13D/G signal
—
Evidence rows
6
Latest as of
30 Sep 2025
13F
3/4/5
Lead comparable stake: 0.55%
Rank 1 holder
Marex Group plc
13F
- Ownership
- 0.55%
- Position
- $119.7K
Rank 2 holder
Virtu Financial LLC
13F
- Ownership
- 0.33%
- Position
- $71K
Rank 3 holder
MORGAN STANLEY
13F
- Ownership
- 0%
- Position
- $2
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Marex Group plc |
13F
Company
|
0.55%
|
$119,729
70,429 shares
|
— | 30 Sep 2025 |
| Virtu Financial LLC |
13F
Company
|
0.33%
|
$71,000
41,677 shares
|
— | 30 Sep 2025 |
| MORGAN STANLEY |
13F
Company
|
0%
|
$2
1 shares
|
— | 30 Sep 2025 |
| Josef Zelinger |
3/4/5
Director
|
—
mixed-class rows
|
—
15,002,805 shares
mixed-class rows
|
— | 05 Jul 2023 |
| James Andrew Nathanielsz |
3/4/5
CEO/CFO, Director
|
—
class O/S missing
|
—
8,728,004 shares
|
— | 17 Aug 2021 |
| Julian Norman Kenyon |
3/4/5
Chief Scientific Officer, Director
|
—
class O/S missing
|
—
3,420,005 shares
|
— | 17 Aug 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
4
Shares
128,890
Rows available
4
| Investor | Option | Weight % | Change % | Reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that failed the local validity check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
3
Q4 2025 holders
4
Holder diff
1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend